SAN MATEO, Calif.--(BUSINESS WIRE)--Templeton Asset Management Ltd. (“Templeton Emerging Markets Team”) today rejected Sun Pharmaceutical’s (“Sun”) tender offer for Taro Pharmaceutical (“Taro”) shares. Mark Mobius, executive chairman of Templeton Asset Management, said, “The offer is not acceptable to us as we strongly believe that it undervalues Taro Pharmaceutical.”
